Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 July 2024
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 February 2024
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 May 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 February 2023
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2022
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA836)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2022
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 August 2022
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 August 2022
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence (TA810)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 July 2022
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2022
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 April 2022
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) (TA762)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA725)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 September 2021
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (TA704)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 May 2021
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA687)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 March 2021
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 July 2020
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 June 2020
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 May 2020
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 November 2019
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2019
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 February 2019
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2018
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 March 2018
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 January 2018
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 January 2018
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2017
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2017
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 November 2017Published: 19 July 2017
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 December 2016
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 December 2016
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 December 2016
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 October 2012
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 August 2012
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 June 2012
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2011
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 February 2011
Gemcitabine for the treatment of metastatic breast cancer (TA116)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 January 2007
Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 March 2002
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 March 2025
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 June 2025
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 10 September 2025
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer TS ID 11910Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years TS ID 12116Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy ID6509Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC